Loading…
Loading…
It operates as an exchange-traded investment fund.
Is ASD's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
ETFs allow investors a plethora of ways to express themselves while also pursuing performance. With each passing year, new ETFs arrive to help investors meet their personal and financial goals.
The arrival of June usually signals a seasonal slowdown for many people, but our ETF industry clearly missed the memo. Instead of heading to the beach or stopping to watch the World Cup, the ETF ecosystem had a wave of milestones, structural changing-of-the-guards, and high-profile index provider consolidation.
June has seen many ETF launches, from pure-play AI memory chip thematics to an autism impact fund that donates returns to nonprofits. With a record breaking 214 launches, the ETF landscape continues to expand into new markets.
The ETF ecosystem is always changing and growing. Thanks to the ETF's flexibility, transparency, and tradability, it can help investors achieve plenty of bespoke goals.
SAN FRANCISCO and BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced topline results from IRIS (ML-004-002), a Phase 2 study of ML-004 in autism spectrum disorder (ASD). The study randomized 161 participants (102 adolescents, 59 adults), with prespecified analyses planned by age group and baseline irritability severity.